

## **Spectrum Antimicrobials, Inc. Announces US FDA Clearance for Marketing Spectricept™ Skin & Wound Cleanser**

Petaluma, Calif. – January 29, 2023. Spectrum Antimicrobials, Inc., a subsidiary of Collision, Inc., announces its first 510K clearance for marketing Spectricept™ Skin & Wound Cleanser by US FDA. Spectricept™ is the first novel composition of HOCl chemistry that is cleared for moistening, irrigation, and debridement of a wide range of chronic and acute wounds as Rx and as an OTC product. The recently patented formula contains a proprietary mixture of HOCl and metal salts.

Developed as a topical treatment, the modified Hypochlorous Acid (HOCl) chemistry contains HOCl in combination with stabilizing metal salts. These stabilizers play a crucial role in preventing HOCl from being instantly neutralized when in contact with organic materials including body serum and wound exudate. Wound care is generally performed in non-sterile environments and all such wounds have potential for developing an infection caused by a variety of pathogens including antibiotic resistant bacteria (ARB's) such as MRSA, VRE, amongst many other types of ARB's.

According to the Centers for Disease Control (CDC) nosocomial infections result from complications that occur in healthcare facilities and they are linked with high morbidity and mortality. On any given day, 1 in 31 hospital patients develop an infection (nosocomial infections). Many Hospital Acquired Infections (HAI's) are caused by the most serious antibiotic-resistant bacteria and can lead to sepsis or death. The CDC estimates that HAIs account for an estimated 1.7 million infections and 99,000 associated deaths each year and impose \$12.8B in direct medical costs each year in the U.S.

GLP studies have confirmed that *Spectricept™* is highly potent and effective against infectious diseases including antibiotic resistant bacteria and aids in protection against spread of infection when used in accordance with the label cleared by FDA. We plan to conduct cost benefit studies to document the economic savings which may result from using Spectricept™ in management of wounds within hospital settings.

We further plan to conduct a number of drug studies under Investigational New Drug applications (IND), where we plan to demonstrate the safety, efficacy and superiority of our advanced solutions to existing antimicrobial products in the marketplace.

Modes of action for eradication of pathogens using hypochlorous acid have been well studied, peer reviewed and published. Such scientific modes of action differ at the molecular level when eradicating viruses, bacteria, fungi and or spores. HOCl generally causes the bacterial cell membrane to become more permeable which results in HOCl entering into cell cytoplasm where it is responsible for interruption of the ATP cycle. By shutting off the energy cycle within the cell, the result causes instantaneous bacterial cell death. In contrast, the fungicidal effects of HOCl are accomplished through interruption of a cascade of molecular events primarily driven by kinase molecules. Peer reviewed and published data demonstrates that the cellular damage caused by

HOCl to bacteria is measured at 100 milliseconds, and such cellular damage is not reversible. Unlike antibiotics and other topical antimicrobials, HOCl does not promote the emergence of new resistant pathogens. Spectricept™ is a patented chemistry of HOCl that is capable of eradicating pathogens in presence of serum.

Hoji Alimi, Founder and CEO of Spectrum Antimicrobials stated, “The issuance of this FDA clearance validates the safety of our novel Spectricept™ Skin and Wound Cleanser product in management of wounds in both RX and OTC markets. Furthermore, this FDA clearance now provides us with a significant platform to submit our next generation hydrogel product to the FDA which will have indications for treatment of burns, dermatological conditions, reduction of topical itch and pain. The market for sale of HOCl based hydrogel products has historically been vastly larger in comparison to the use of liquid solutions. This is due to the use of HOCl solutions to moisten, clean and deride wounds while hydrogels are utilized for continuous moistening of wounds and to avoid gauze and bandages from adhering to the wound bed. The FDA clearance for Spectricept™ liquid product now allows us to file our hydrogel composition with FDA using the same safety information.”

Bill Watson, Co-Founder and Executive Vice President of Business Development and Global Sales added, “We intend to monetize on this FDA clearance by accelerating our discussions with potential industry partners for the sale of Spectricept™ in both the U.S. and abroad. The industry’s continuous reliance on antibiotics has only accelerated the antibiotic resistant pandemic which is costing U.S. hospitals more than \$28b annually. We believe there is genuine and immediate need for the use of Spectricept™ in the management of wounds in all segments of medicine to improve patient outcomes.”

“The peer reviewed published paper in the Lancet in January of 2022, includes the analysis of meta data from around the world pertaining to cases of infection in 2019. This data shows there were over 50 million cases of antibiotic resistant infections that either caused or contributed to over 5 million deaths globally. The World Health Organization has reported that without advances in antimicrobial technology, infections caused by drug resistant microbes could increase mortality rate to ten million people per year by 2050”, added Watson.

### **About Spectrum Antimicrobials, Inc.**

Spectrum Antimicrobials, Inc. is an Infection Control Solutions Company focused on the development and commercialization of platform chemistries and drug formulations created for the prevention, control and treatment of infections in the healthcare industry. Our products use broad spectrum antimicrobial chemistries that are highly effective against bacteria, virus, mold, fungi, and spores, including antibiotic resistant pathogens known as “Superbugs.” These novel platform chemistries were designed as both preventatives and therapeutics to improve patient care, lead to faster healing times, and reduce the hospitals costs of treating hospital acquired infections, which may not be reimbursed by insurers. Our drug formulations are uniquely engineered and do not become inactivated in presence of serum and wound exudates with improved stability which is required to meet drug requirements.